Free Trial

ResMed (RMD) Competitors

ResMed logo
$275.29 +1.79 (+0.65%)
Closing price 07/25/2025 03:59 PM Eastern
Extended Trading
$275.20 -0.09 (-0.03%)
As of 07/25/2025 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

RMD vs. SYK, MDT, BDX, EW, IDXX, DXCM, STE, PODD, HOLX, and BAX

Should you be buying ResMed stock or one of its competitors? The main competitors of ResMed include Stryker (SYK), Medtronic (MDT), Becton, Dickinson and Company (BDX), Edwards Lifesciences (EW), IDEXX Laboratories (IDXX), DexCom (DXCM), STERIS (STE), Insulet (PODD), Hologic (HOLX), and Baxter International (BAX). These companies are all part of the "health care equipment" industry.

ResMed vs. Its Competitors

ResMed (NYSE:RMD) and Stryker (NYSE:SYK) are both large-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, risk, dividends, valuation, media sentiment, analyst recommendations, earnings and institutional ownership.

ResMed presently has a consensus price target of $263.00, suggesting a potential downside of 4.46%. Stryker has a consensus price target of $428.55, suggesting a potential upside of 6.25%. Given Stryker's stronger consensus rating and higher probable upside, analysts plainly believe Stryker is more favorable than ResMed.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ResMed
1 Sell rating(s)
3 Hold rating(s)
10 Buy rating(s)
1 Strong Buy rating(s)
2.73
Stryker
0 Sell rating(s)
4 Hold rating(s)
15 Buy rating(s)
0 Strong Buy rating(s)
2.79

Stryker has higher revenue and earnings than ResMed. ResMed is trading at a lower price-to-earnings ratio than Stryker, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ResMed$4.69B8.62$1.02B$8.9130.90
Stryker$22.60B6.81$2.99B$7.4054.51

ResMed pays an annual dividend of $2.12 per share and has a dividend yield of 0.8%. Stryker pays an annual dividend of $3.36 per share and has a dividend yield of 0.8%. ResMed pays out 23.8% of its earnings in the form of a dividend. Stryker pays out 45.4% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. ResMed has increased its dividend for 13 consecutive years and Stryker has increased its dividend for 32 consecutive years. Stryker is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

In the previous week, Stryker had 22 more articles in the media than ResMed. MarketBeat recorded 38 mentions for Stryker and 16 mentions for ResMed. ResMed's average media sentiment score of 1.34 beat Stryker's score of 1.31 indicating that ResMed is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
ResMed
13 Very Positive mention(s)
2 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Stryker
31 Very Positive mention(s)
1 Positive mention(s)
6 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

ResMed has a net margin of 26.15% compared to Stryker's net margin of 12.31%. ResMed's return on equity of 25.67% beat Stryker's return on equity.

Company Net Margins Return on Equity Return on Assets
ResMed26.15% 25.67% 18.59%
Stryker 12.31%23.74%11.25%

ResMed has a beta of 0.77, suggesting that its stock price is 23% less volatile than the S&P 500. Comparatively, Stryker has a beta of 0.91, suggesting that its stock price is 9% less volatile than the S&P 500.

55.0% of ResMed shares are held by institutional investors. Comparatively, 77.1% of Stryker shares are held by institutional investors. 0.7% of ResMed shares are held by company insiders. Comparatively, 5.9% of Stryker shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Stryker beats ResMed on 12 of the 20 factors compared between the two stocks.

Get ResMed News Delivered to You Automatically

Sign up to receive the latest news and ratings for RMD and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

RMD vs. The Competition

MetricResMedMED PRODUCTS IndustryMedical SectorNYSE Exchange
Market Cap$40.10B$10.55B$5.70B$21.11B
Dividend Yield0.78%2.00%4.60%3.60%
P/E Ratio30.9017.0728.1028.44
Price / Sales8.6229.18429.3858.68
Price / Cash29.6423.0336.2222.92
Price / Book8.313.698.664.69
Net Income$1.02B$234.77M$3.25B$995.51M
7 Day Performance6.85%6.32%4.22%1.65%
1 Month Performance7.33%7.94%10.51%4.54%
1 Year Performance39.71%-13.57%34.40%9.99%

ResMed Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
RMD
ResMed
3.5213 of 5 stars
$275.29
+0.7%
$263.00
-4.5%
+32.1%$40.10B$4.69B30.909,980Positive News
Upcoming Earnings
SYK
Stryker
4.5365 of 5 stars
$387.58
-0.5%
$428.55
+10.6%
+23.2%$147.94B$22.60B52.3853,000Positive News
Upcoming Earnings
MDT
Medtronic
4.6569 of 5 stars
$89.76
+0.2%
$98.19
+9.4%
+18.5%$115.12B$33.54B24.8095,000Positive News
BDX
Becton, Dickinson and Company
4.8276 of 5 stars
$175.49
-1.9%
$219.22
+24.9%
-20.3%$50.30B$20.18B33.4974,000Positive News
Dividend Announcement
Insider Trade
EW
Edwards Lifesciences
4.3573 of 5 stars
$76.57
+0.1%
$81.00
+5.8%
+33.9%$44.91B$5.44B10.9415,800Trending News
Earnings Report
Analyst Forecast
Gap Up
IDXX
IDEXX Laboratories
3.5802 of 5 stars
$520.87
+1.2%
$560.33
+7.6%
+20.1%$41.89B$3.90B48.1411,000Positive News
DXCM
DexCom
4.7283 of 5 stars
$84.03
+0.2%
$99.60
+18.5%
-17.5%$32.95B$4.03B62.7110,300Upcoming Earnings
STE
STERIS
4.7945 of 5 stars
$222.55
-1.3%
$266.50
+19.7%
+1.6%$21.89B$5.46B35.9017,787Analyst Forecast
PODD
Insulet
4.5952 of 5 stars
$280.96
-1.2%
$321.00
+14.3%
+52.0%$19.77B$2.07B50.533,900Positive News
HOLX
Hologic
4.7313 of 5 stars
$63.69
-0.5%
$77.33
+21.4%
-14.6%$14.19B$4.03B26.877,063Positive News
Upcoming Earnings
Analyst Revision
BAX
Baxter International
4.3157 of 5 stars
$27.40
-1.3%
$36.38
+32.7%
-16.7%$14.06B$10.77B-24.9138,000Upcoming Earnings

Related Companies and Tools


This page (NYSE:RMD) was last updated on 7/26/2025 by MarketBeat.com Staff
From Our Partners